RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hyloris Pharmaceuticals Stock

Hyloris Pharmaceuticals Liabilities 2024

Hyloris Pharmaceuticals Liabilities

8.61 M EUR

Ticker

HYL.BR

ISIN

BE0974363955

WKN

A2P7Y0

In 2024, Hyloris Pharmaceuticals's total liabilities amounted to 8.61 M EUR, a 26.29% difference from the 6.82 M EUR total liabilities in the previous year.

Hyloris Pharmaceuticals Aktienanalyse

What does Hyloris Pharmaceuticals do?

Hyloris Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Hyloris Pharmaceuticals's Liabilities

Hyloris Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Hyloris Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Hyloris Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Hyloris Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Hyloris Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Hyloris Pharmaceuticals stock

What is the level of liabilities of Hyloris Pharmaceuticals this year?

Hyloris Pharmaceuticals has a debt balance of 8.61 M EUR this year.

What were the liabilities of Hyloris Pharmaceuticals compared to the previous year?

The liabilities of Hyloris Pharmaceuticals have increased by 26.29% increased compared to the previous year.

What are the consequences of high debt for investors of Hyloris Pharmaceuticals?

High liabilities can pose a risk for investors of Hyloris Pharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Hyloris Pharmaceuticals?

Low liabilities mean that Hyloris Pharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Hyloris Pharmaceuticals affect the company?

An increase in liabilities of Hyloris Pharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Hyloris Pharmaceuticals affect the company?

A decrease in the liabilities of Hyloris Pharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Hyloris Pharmaceuticals?

Some factors that can influence the liabilities of Hyloris Pharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Hyloris Pharmaceuticals so important for investors?

The liabilities of Hyloris Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Hyloris Pharmaceuticals take to modify the liabilities?

To change its liabilities, Hyloris Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Hyloris Pharmaceuticals pay?

Over the past 12 months, Hyloris Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hyloris Pharmaceuticals is expected to pay a dividend of 0 EUR.

What is the dividend yield of Hyloris Pharmaceuticals?

The current dividend yield of Hyloris Pharmaceuticals is .

When does Hyloris Pharmaceuticals pay dividends?

Hyloris Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hyloris Pharmaceuticals?

Hyloris Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hyloris Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hyloris Pharmaceuticals located?

Hyloris Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hyloris Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hyloris Pharmaceuticals from 11/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Hyloris Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Hyloris Pharmaceuticals in the year 2023?

In the year 2023, Hyloris Pharmaceuticals distributed 0 EUR as dividends.

In which currency does Hyloris Pharmaceuticals pay out the dividend?

The dividends of Hyloris Pharmaceuticals are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hyloris Pharmaceuticals

Our stock analysis for Hyloris Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hyloris Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.